COMBINED TREATMENT FOR CHRONIC MIGRAINE: BOTULINUM TOXIN TYPE A AND VENLAFAXINE


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The paper presents the combined use of botulinum toxin type A and the antidepressant venlafaxine in patients with chronic migraine. The findings indicate the efficacy and safety of the proposed therapeutic strategy that has simultaneously an impact on different pathophysiological mechanisms of migraine as a primary disease and on comorbidities and modifiable factors for chronicity of headache, the most important of which are depression and excessive use of analgesics.

全文:

受限制的访问

作者简介

K. Tatarinova

I.M. Sechenov First Moscow State Medical University (Sechenov University); A.S. Lukashevsky Kamchatka Territorial Hospital

Email: doctor-karina@yandex.ru

A. Artemenko

I.M. Sechenov First Moscow State Medical University (Sechenov University)

参考

  1. Ayzenberg I., Katsarava Z., Sborowski A. et al. The prevalence of primary headache disorder in Russia: a countrywide survey // Cephalalgia. - 2012; 32 (5): 373-81.
  2. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version) // Cephalalgia. - 2013; 33 (9): 629-808.
  3. Артеменко А.Р., Куренков А.Л., Беломестова К.В. Классификация, диагностика и лечение хронической мигрени: обзор новых данных // Журн. неврол. и психиат. - 2013; 113 (11): 91-6.
  4. Осипова В.В., Вознесенская Т.Г. Коморбидность мигрени: обзор литературы и подходы к изучению // Журн. неврол. и психиат. - 2007; 107 (3): 64-71.
  5. Silberstein S. Preventive migraine treatment // Continuum (Minneap Minn). -2015; 21 (4): 973-89.
  6. Silberstein S., Lipton R., Dodick D. et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures // Headache. - 2009; 49 (8): 1153-62.
  7. Aurora S., Dodick D., Turkel C. et al. Onabotulinum-toxin A for treatment of chronic migraine: Result from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial // Cephalalgia. - 2010; 30: 793-803.
  8. Diener H., Dodick D., Aurora S. et al. Onabotulinum-toxin A for treatment of chronic migraine: Result from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial // Cephalalgia. - 2010; 30: 804-14.
  9. Латышева Н.В., Филатова Е.Г., Табеева Г.Р. и др. Практические вопросы ведения пациентов с хронической мигренью. Рекомендации российских экспертов // Нервно-мышечные болезни. - 2015; 3: 31-6.
  10. D’Amico D., Curone M., Tullo V. et al. Polytherapy for the prophylaxis of chronic migraine: an Italian survey // Neurol. Sci. - 2011; 32 (Suppl. 1): 185-8.
  11. Peterlin B., Calhoun A., Sherry S. et al. Rational combination therapy in refractory migraine // Headache. - 2008; 48: 805-19.
  12. Wiendels N., van Haestregt A., Knuistingh Neven A. et al. Chronic frequent headache in the general population: comorbidity and quality of life // Cephalalgia. -2010; 26 (12): 1443-50.
  13. Buse D., Manack A., Serrano D. et al. Sociodemogaphic and comorbidity profiles of chronic migraine and episodic migraine sufferers // J. Neurol. Neurosurg. Psychiatry. - 2010; 81 (4): 428-32.
  14. Krymchantowski A., Silva M., Barbosa J. et al. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a doubleblind study // Headache. - 2002; 42: 510-4.
  15. Domingues R., Silva A., Domingues S. et al. A double-blind randomized controlled trial of low dose of propranolol, nortrypiline, and the combination of propranolol and nortryptiline for the preventive treatment of migraine // Arq. Neuropsiquiatr. - 2009; 67 (4): 973-7.
  16. Krymchantowski A., Hampshire F. Polytherapy in migraine prevention. Clinical experience with the combination of a tricyclic antidepressant plus a calcium channel blocker // Headache. - 2004; 44: 499-500.
  17. Pascual J., Rivas M., Leira R. Testing the combination betablocker plus topiramate in refractory migraine // Acta Neurol. Scand. - 2007; 115: 81-3.
  18. Aoki K. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A // Neurotoxicology. - 2005; 26: 785-93.
  19. Татаринова К.В., Артеменко А.Р. Влияние клинических проявлений мигрени, депрессии и нарушения сна на качество жизни пациентов с хронической мигренью // Нервно-мышечные болезни. - 2017; 7 (1): 43-53.
  20. Латышева Н.В., Филатова Е.Г. Эффективность венлафаксина при хронической ежедневной головной боли // Лечащий врач. - 2008; 5: 1-5.
  21. Bulut S., Berilgen M., Baran A. et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: Randomized, double-blind, crossover study // Clin. Neurol. Neurosurg. - 2004; 107: 44-8.
  22. Ozyalcin S., Talu G., Kiziltan E. et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine // Headache. - 2005; 45: 144-52.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##